April 24, 2026 — The U.S. Food and Drug Administration's PreCheck Pilot Program, which began accepting applications in February 2026, represents the most significant regulatory initiative in decades aimed at reshoring pharmaceutical manufacturing to American soil. For API producers, FDF manufacturers, and CDMOs evaluating capacity expansion in the United States, PreCheck offers a streamlined, predictable pathway that could fundamentally alter the economics and timelines of new facility development.
The PreCheck Pilot Program is designed to strengthen the domestic pharmaceutical supply chain by increasing regulatory predictability, facilitating the construction of manufacturing sites in the United States, and streamlining facility assessments in advance of a specific product application. Unlike traditional FDA inspections that occur after a facility is built and operational, PreCheck engages with manufacturers during the design, construction, and pre-operational phases.
The program operates in two distinct phases:
Phase I — Facility Readiness: Selected manufacturers receive early technical advice through pre-operational reviews and can establish a facility-specific Drug Master File (DMF) to facilitate evaluation of facility-specific elements before submitting a drug application
Phase II — Application Submission: Pre-submission meetings and inspections resolve potential issues early, expediting the assessment process when formal drug applications (NDA/ANDA/BLA/DMF supplements) are filed
FDA Commissioner Marty Makary framed the initiative in stark terms: "After 35 years of globalists taking pharmaceutical manufacturing overseas, the FDA is taking bold steps to bring it back." The program's ambition is clear — to reverse decades of offshoring by making domestic facility construction faster, cheaper, and more predictable from a regulatory standpoint.
The program targets new manufacturing facilities that are in the design, construction, or pre-operational stages. Key eligibility criteria include:
Facilities must be new — not existing sites or extensions of operational facilities. Participants must have broken ground or plan to break ground before May 1, 2026
Facilities must be located in the United States or its insular areas
Participants must commit to submitting a new drug application, ANDA, BLA, supplement, or Type II DMF for the facility
Participants must commit to actively manufacturing products in the facility for at least three years following FDA approval
Notably, facility size thresholds are flexible. The FDA has indicated that "a small volume may be acceptable if it fully meets the needs for a rare disease state with a limited patient population." This opens the program to specialty and orphan drug manufacturers alongside large-scale commercial producers.
The PreCheck program directly addresses one of the most persistent barriers to domestic pharmaceutical manufacturing: regulatory uncertainty. For decades, companies investing in U.S. manufacturing facilities faced a binary risk — build first, then hope the FDA approves the site during inspection. A failed inspection could render a $100+ million facility unusable for months or years.
PreCheck inverts this model by providing early, iterative FDA engagement throughout the construction process. For API and FDF manufacturers, this translates into several tangible benefits:
Reduced regulatory risk: Early feedback on facility design, equipment qualification, and quality systems reduces the probability of costly post-construction modifications
Faster time to market: By resolving facility-level issues before product application submission, companies can compress the total timeline from groundbreaking to first commercial batch
Investor confidence: Regulatory predictability de-risks capital investment, making it easier to secure financing for new domestic manufacturing projects
Competitive positioning: Companies that participate in PreCheck and establish facility-specific DMFs will have a head start when applying for product approvals at their new sites
PreCheck is one component of a broader U.S. policy push to reduce dependence on foreign pharmaceutical manufacturing. China currently supplies approximately 40% of global APIs by volume, and India provides roughly 47% of U.S. generic prescription volume. The COVID-19 pandemic exposed the fragility of these concentrated supply chains, and geopolitical tensions have reinforced the strategic imperative for diversification.
Additional policy measures supporting domestic manufacturing include:
Executive orders on pharmaceutical supply chain security: Multiple executive actions have directed federal agencies to prioritize domestic manufacturing of essential medicines
National priority review vouchers: Drugs manufactured domestically or aligned with national health priorities receive dramatically accelerated FDA review timelines — potentially as short as one to two months
Proposed tariff structures: Discussions around pharmaceutical import tariffs could further shift the cost calculus in favor of domestic production
Federal procurement preferences: Government healthcare programs may increasingly favor domestically manufactured drugs, creating demand signals for U.S.-based API and FDF producers
The PreCheck program carries mixed implications for international CDMOs and API manufacturers. On one hand, the program's focus on domestic facilities could be perceived as a competitive threat to overseas manufacturers. On the other hand, several dynamics create opportunities for international players:
Joint ventures and partnerships: International CDMOs with process expertise can partner with U.S.-based companies to establish domestic manufacturing, transferring technology while leveraging PreCheck's streamlined pathway
U.S. facility investment: Companies from India, China, Europe, and Japan that invest in new U.S. manufacturing sites are eligible for PreCheck participation, potentially accelerating their American expansion
Specialty API manufacturing: The program's flexibility around facility size opens opportunities for niche, high-value API manufacturing that may not justify mega-facility investment but can thrive in specialized U.S. plants
Major Indian API manufacturers including Dr. Reddy's, Aurobindo, and Sun Pharma — which already operate FDA-inspected facilities in the United States — are closely evaluating PreCheck eligibility for planned capacity expansions. Similarly, European CDMOs like Lonza and Siegfried may leverage the program to accelerate greenfield investments.
The pharmaceutical manufacturing landscape is already shifting. The API CDMO market is projected to reach $221 billion by 2032, growing at a 9.7% CAGR. PreCheck could accelerate the U.S. share of this growth by reducing barriers to domestic facility construction.
Early PreCheck participants will gain several competitive advantages:
First-mover facility DMFs: Companies that establish facility-specific DMFs during PreCheck will have regulatory documentation ready when product opportunities arise — a significant advantage in the fast-moving generic and biosimilar markets
Customer confidence: Pharmaceutical companies seeking domestic manufacturing partners will prefer PreCheck-participating facilities, as the early FDA engagement provides an additional layer of quality assurance
Talent acquisition: Facilities with regulatory clarity can recruit skilled pharmaceutical manufacturing workers more effectively, addressing a critical bottleneck in domestic capacity expansion
For API manufacturers, intermediate suppliers, and CDMOs evaluating their strategic positioning in light of PreCheck, several actions merit consideration:
Evaluate PreCheck eligibility: If you are planning a new U.S. manufacturing facility, assess whether your project meets the program's criteria and consider submitting an application for future cohorts
Engage regulatory counsel early: The PreCheck application process requires detailed facility plans and manufacturing commitments. Legal and regulatory advisors with FDA facility experience can maximize your chances of selection
Consider strategic partnerships: International API manufacturers without existing U.S. facilities can explore joint ventures with domestic partners to access PreCheck benefits
Align with national priority areas: Facilities focused on essential medicines, rare disease drugs, or shortage-list products may receive preferential consideration in the PreCheck selection process
Build flexible capacity: Design facilities with multi-product capability to maximize the return on domestic manufacturing investment. PreCheck's early engagement model supports iterative design optimization
The FDA PreCheck Pilot Program is still in its early stages, with the first cohort of participants expected to begin PreCheck activities in 2026. However, the program's structural logic — providing regulatory certainty before capital commitment — is likely to become a permanent feature of the FDA's facility assessment framework.
For the pharmaceutical supply chain, the implications are profound. If PreCheck succeeds in accelerating domestic facility construction, it will create a new wave of demand for equipment suppliers, construction contractors, analytical service providers, and, ultimately, API and intermediate manufacturers serving the expanding U.S. production base. Companies that position themselves early in this emerging ecosystem will capture outsized value as American pharmaceutical manufacturing enters a new chapter.
